Givinostat

Givinostat (ITF2357) is a small-molecule drug developed by Italfarmaco. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the stre. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06093672 (Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera), in myeloproliferative neoplasms. The largest, NCT06093672, plans to enrol 220 participants with primary completion expected 2026-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.